Listas de Observação Ideias ProPicks IA Filtros Explorador de dados Gráficos Guardado

Dermapharm Holding SE

DB:DMP

Alemanha / Saúde / Farmacêutica

Resumo

Histórico Financeiro 10A

Preço Ação

40,50 EUR


Key Metrics	Latest
Total Revenue	1,174 B
Adjusted EBITDA	234,7 M
EBITDA Margin	20,0%
Net Profit Margin	8,2%
Total Assets	2,123 B
Total Debt	1,025 B

10Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending										Latest
(in millions)	Dec-14	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	12 Months

Revenue	402	396	455	480	584	714	808	960	1,041	1,151	1,174
% Growth		-1.5%	14.9%	5.4%	21.8%	22.3%	13.1%	18.8%	8.4%	10.6%

Adjusted EBITDA	58	75	90	95	120	131	155	312	302	220	235
% Margin	14.4%	19.0%	19.7%	19.8%	20.6%	18.3%	19.2%	32.5%	29.1%	19.1%	20.0%

Adjusted EBIT	53	70	85	90	113	120	140	296	283	193	214
% Margin	13.2%	17.7%	18.6%	18.7%	19.3%	16.9%	17.3%	30.8%	27.2%	16.8%	18.3%

Adjusted Net Income	32	48	76	77	79	78	88	209	162	67	96
% Margin	7.9%	12.1%	16.6%	16.1%	13.4%	10.9%	10.9%	21.8%	15.6%	5.8%	8.2%

Adjusted Basic EPS	NA	NA	1.51	1.54	1.47	1.45	1.64	3.88	3.01	1.25	1.78

Cálculos de Suporte

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
											Original
EUR	Fiscal Year Ending										Latest
(in millions)	Dec-14	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Sep-24
	FY - 9	FY - 8	FY - 7	FY - 6	FY - 5	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM

Revenue	402	396	455	480	584	714	808	960	1,041	1,151	1,174
% Growth	NA	-1.5%	14.9%	5.4%	21.8%	22.3%	13.1%	18.8%	8.4%	10.6%

Cost of Revenue	(229)	(213)	(255)	(260)	(289)	(337)	(354)	(350)	(392)	(447)	(440)
Gross Profit	173	183	200	219	295	377	454	610	649	704	734
% Revenue	43.1%	46.2%	43.9%	45.7%	50.5%	52.8%	56.2%	63.6%	62.3%	61.2%	62.6%

Research and Development	(12)	(5)	(5)	(7)	(6)	(2)	(6)	(20)	(21)	(20)	(20)
Selling and Marketing	(7)	(7)	(7)	(9)	0	0	0	0	0	0	0
General and Admin	(60)	(58)	(63)	(69)	(92)	(116)	(158)	(169)	(191)	(271)	(283)
Other Inc / (Exp)	(84)	(90)	(35)	(41)	(88)	(141)	(156)	(123)	(209)	(255)	(242)
Total Operating Exp	(163)	(160)	(111)	(126)	(186)	(259)	(320)	(312)	(420)	(546)	(544)

Operating Income	11	23	89	93	108	118	134	298	228	158	190
% Revenue	2.6%	5.8%	19.5%	19.5%	18.6%	16.5%	16.6%	31.0%	21.9%	13.8%	16.2%

Interest Expense	(8)	(7)	(6)	(5)	(4)	(8)	(9)	(5)	(12)	(52)	(48)
Pre-tax Income	2	16	83	88	104	110	125	293	216	106	142
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0	0	0	0
Provision for Taxes	(2)	(3)	(6)	(10)	(29)	(32)	(39)	(84)	(84)	(45)	(52)
Net Income to Company	0	13	77	78	75	78	86	209	133	61	89
% Margin	0.1%	3.3%	16.9%	16.2%	12.9%	10.9%	10.6%	21.8%	12.7%	5.3%	7.6%

Minority Interest in Earnings	(0)	(0)	(0)	0	0	(1)	(0)	1	2	2	1
Net Income to Stockholders	(0)	13	77	78	75	77	86	210	134	62	91

Preferred Dividends	0	0	0	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0	0	0	0

Net Income to Common	(0)	13	77	78	75	77	86	210	134	62	91
% Margin	0.0%	3.2%	16.9%	16.2%	12.9%	10.8%	10.6%	21.8%	12.9%	5.4%	7.7%

As Reported
Basic EPS (Continuing Ops)	0.00	0.00	1.54	1.56	1.41	1.43	1.59	3.89	2.49	1.16	1.68
Diluted EPS (Continuing Ops)	0.00	0.00	1.54	1.56	1.41	1.43	1.59	3.89	2.49	1.16	1.68

WA Basic Shares Out.	0.00	0.00	49.88	49.94	53.42	53.84	53.84	53.84	53.84	53.84	53.99
WA Diluted Shares Out.	0.00	0.00	49.88	49.94	53.42	53.84	53.84	53.84	53.84	53.84	53.99

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	2	16	83	88	104	110	125	293	216	106	142
Addback: Net Interest Expense	8	7	6	5	4	8	9	5	12	52	48
Addback: Other Non Operating Expenses, Total	(0)	(0)	(2)	(3)	(0)	2	3	(2)	14	26	16
Addback: Depreciation & Amortization	5	5	5	5	8	10	15	16	20	27	20
Addback: Restructuring Charges	0	0	0	0	0	0	0	1	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	5	5	0	0	0	0	0	5	36	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	(0)	0	0	0	0	(9)	0	2	2
Addback: Gain (Loss) On Sale Of Assets	0	3	0	0	0	0	(0)	(1)	(3)	(3)	(3)
Addback: Asset Writedown	5	0	0	0	6	2	4	4	7	16	16
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
Addback: Legal Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	33	39	(1)	(1)	(2)	(1)	0	0	0	(6)	(6)
Adjusted EBITDA	58	75	90	95	120	131	155	312	302	220	235
% Margin	14.4%	19.0%	19.7%	19.8%	20.6%	18.3%	19.2%	32.5%	29.1%	19.1%	20.0%

Adjusted EBIT	53	70	85	90	113	120	140	296	283	193	214
% Margin	13.2%	17.7%	18.6%	18.7%	19.3%	16.9%	17.3%	30.8%	27.2%	16.8%	18.3%

Adjusted Net Income Reconciliation
Net Income to Company	0	13	77	78	75	78	86	209	133	61	89
Addback: Unusual Items	43	47	(2)	(1)	5	0	3	(0)	40	9	9
Less: Tax Benefit of Unusual Items (26%)	(11)	(12)	1	0	(1)	(0)	(1)	0	(10)	(2)	(2)
Adjusted Net Income	32	48	76	77	79	78	88	209	162	67	96
% Margin	7.9%	12.1%	16.6%	16.1%	13.4%	10.9%	10.9%	21.8%	15.6%	5.8%	8.2%

Erro de carregamento

Dermapharm Holding SE

DB:DMP

Alemanha / Saúde / Farmacêutica

Histórico Financeiro 10A